Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.

artificial tears cornea dry eye disease excipients ingredients ocular surface tear film tear substitutes

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Feb 2022
Historique:
received: 23 11 2021
revised: 17 12 2021
accepted: 18 12 2021
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 30 3 2022
Statut: epublish

Résumé

Dry eye disease (DED) is the most common ocular surface disease, characterized by insufficient production and/or instability of the tear film. Tear substitutes are usually the first line of treatment for patients with DED. Despite the large variety of tear substitutes available on the market, few studies have been performed to compare their performance. There is a need to better understand the specific mechanical and pharmacological roles of each ingredient composing the different formulations. In this review, we describe the main categories of ingredients composing tear substitutes (e.g., viscosity-enhancing agents, electrolytes, osmo-protectants, antioxidants, lipids, surfactants and preservatives) as well as their effects on the ocular surface, and we provide insight into how certain components of tear substitutes may promote corneal wound healing, and/or counteract inflammation. Based on these considerations, we propose an approach to select the most appropriate tear substitute formulations according to the predominant etiological causes of DED.

Identifiants

pubmed: 35269576
pii: ijms23052434
doi: 10.3390/ijms23052434
pmc: PMC8910031
pii:
doi:

Substances chimiques

Lubricant Eye Drops 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Physiol Rev. 2011 Jan;91(1):221-64
pubmed: 21248167
Eye Contact Lens. 2020 Jan;46 Suppl 1:S2-S13
pubmed: 31425351
Ophthalmology. 2002 Nov;109(11):2024-9
pubmed: 12414409
Curr Eye Res. 2015 Jul;40(7):657-67
pubmed: 25271595
Mol Vis. 2014 Sep 12;20:1243-52
pubmed: 25352733
Curr Eye Res. 2017 Mar;42(3):358-363
pubmed: 27163340
Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):425-30
pubmed: 25398660
Eur J Ophthalmol. 2018 Jan;28(1):25-31
pubmed: 28777385
J Control Release. 2020 May 10;321:1-22
pubmed: 32027938
J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):188-194
pubmed: 28771380
Int J Mol Sci. 2020 May 15;21(10):
pubmed: 32429217
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642-8652
pubmed: 32964952
J Clin Med. 2021 Mar 21;10(6):
pubmed: 33800965
Ocul Immunol Inflamm. 2021 Aug 11;:1-9
pubmed: 34379560
Cornea. 2008 Jun;27(5):574-9
pubmed: 18520508
Ocul Surf. 2015 Jan;13(1):26-42
pubmed: 25557344
Curr Eye Res. 2017 Aug;42(8):1108-1114
pubmed: 28441078
Exp Eye Res. 2017 Oct;163:17-28
pubmed: 28950936
J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):355-365
pubmed: 32493105
J Ocul Pharmacol Ther. 2021 Sep;37(7):386-393
pubmed: 34227851
Arch Soc Esp Oftalmol. 2006 Feb;81(2):85-92
pubmed: 16511715
Eur J Ophthalmol. 2017 Aug 30;27(5):520-530
pubmed: 28362054
Nat Med. 2005 Nov;11(11):1173-9
pubmed: 16244651
J Ophthalmol. 2018 Aug 1;2018:4691417
pubmed: 30155282
Surv Ophthalmol. 2001 Mar;45 Suppl 2:S203-10
pubmed: 11587144
J Cell Biol. 1993 Jul;122(1):257-64
pubmed: 8314845
Ocul Surf. 2017 Jul;15(3):334-365
pubmed: 28736337
Curr Eye Res. 2011 Nov;36(11):979-88
pubmed: 21999224
Vet Ophthalmol. 2010 May;13(3):144-50
pubmed: 20500713
Ocul Surf. 2017 Jul;15(3):366-403
pubmed: 28736338
Int J Mol Sci. 2017 Jul 18;18(7):
pubmed: 28718823
Clin Ophthalmol. 2015 Apr 15;9:665-75
pubmed: 25931807
J Drug Deliv. 2012;2012:604204
pubmed: 22506123
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES13-DES22
pubmed: 30481801
Clin Ophthalmol. 2011;5:783-90
pubmed: 21750611
BMC Ophthalmol. 2020 Aug 1;20(1):315
pubmed: 32738875
Clin Ophthalmol. 2018 Jul 12;12:1237-1243
pubmed: 30034217
Nutrients. 2021 Jun 10;13(6):
pubmed: 34200595
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1333-40
pubmed: 22580989
Eye Contact Lens. 2014 Mar;40(2):106-10
pubmed: 24552755
BMC Ophthalmol. 2007 Mar 29;7:5
pubmed: 17394642
Pharmaceutics. 2021 Feb 03;13(2):
pubmed: 33546193
Biochim Biophys Acta. 2011 Sep;1812(9):1170-81
pubmed: 21723389
Exp Eye Res. 2009 Sep;89(3):311-8
pubmed: 19345212
Mol Vis. 2018 Jul 20;24:459-470
pubmed: 30078983
Graefes Arch Clin Exp Ophthalmol. 1995 Nov;233(11):694-8
pubmed: 8566825
J Ocul Pharmacol Ther. 2018 May;34(4):360-364
pubmed: 29394128
Optom Vis Sci. 2005 Jul;82(7):594-601
pubmed: 16044071
J Fr Ophtalmol. 2014 Oct;37(8):589-98
pubmed: 25127703
Invest Ophthalmol Vis Sci. 1985 Nov;26(11):1484-8
pubmed: 2414247
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67
pubmed: 17389485
Cochrane Database Syst Rev. 2016 Feb 23;2:CD009729
pubmed: 26905373
Clin Ophthalmol. 2011;5:577-81
pubmed: 21654884
Front Pharmacol. 2019 Oct 18;10:1240
pubmed: 31680988
Adv Exp Med Biol. 1998;438:753-60
pubmed: 9634964
Cont Lens Anterior Eye. 2012 Oct;35(5):203-7; quiz 243-4
pubmed: 22705318
Clin Ophthalmol. 2018 Apr 10;12:695-700
pubmed: 29692601
BMC Ophthalmol. 2011 Apr 21;11:8
pubmed: 21510881
J Ocul Pharmacol Ther. 2017 Nov;33(9):647-661
pubmed: 28956698
Cornea. 2012 May;31(5):472-8
pubmed: 22378109
Exp Eye Res. 2021 Oct;211:108723
pubmed: 34384756
Cornea. 2012 Nov;31(11):1319-29
pubmed: 22929154
Int J Mol Sci. 2021 Mar 09;22(5):
pubmed: 33803116
Cornea. 2008 Dec;27(10):1126-30
pubmed: 19034126
Expert Opin Drug Deliv. 2021 Jul;18(7):819-847
pubmed: 33412914
J Drug Target. 2004;12(9-10):623-33
pubmed: 15621688
J Ocul Pharmacol Ther. 2015 Oct;31(8):491-7
pubmed: 26067908
Clin Exp Pharmacol Physiol. 2020 Dec;47(12):1883-1890
pubmed: 32621549
Ophthalmology. 1992 Apr;99(4):600-4
pubmed: 1584579
Ocul Surf. 2017 Jul;15(3):511-538
pubmed: 28736341
Am J Ophthalmol. 2009 Feb;147(2):206-213.e3
pubmed: 18848318
Cornea. 2007 Feb;26(2):175-81
pubmed: 17251808
Ocul Surf. 2017 Jul;15(3):575-628
pubmed: 28736343
J Fr Ophtalmol. 2007 Mar;30(3):239-46
pubmed: 17417148
Biomolecules. 2020 May 25;10(5):
pubmed: 32466265
Ocul Surf. 2017 Jul;15(3):276-283
pubmed: 28736335
Eur J Ophthalmol. 2016 Nov 4;26(6):546-555
pubmed: 27515572
Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6287-97
pubmed: 23970467
Ophthalmic Physiol Opt. 2009 Nov;29(6):573-83
pubmed: 19686307
Biochim Biophys Acta. 2016 Oct;1858(10):2421-2430
pubmed: 26898663
Curr Eye Res. 1992 Oct;11(10):981-6
pubmed: 1451529
Ocul Surf. 2013 Oct;11(4):246-58
pubmed: 24112228
Cont Lens Anterior Eye. 2010 Apr;33(2):83-7
pubmed: 20096622
Cont Lens Anterior Eye. 2018 Feb;41(1):93-96
pubmed: 29223649
Cont Lens Anterior Eye. 2018 Feb;41(1):97-100
pubmed: 28943018
Ocul Surf. 2020 Oct;18(4):604-612
pubmed: 32682082
Front Cell Infect Microbiol. 2019 Apr 24;9:117
pubmed: 31069176
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):26
pubmed: 32785678

Auteurs

Marc Labetoulle (M)

Service d'Ophtalmologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, 94270 Le Kremlin Bicêtre, France.

Jose Manuel Benitez-Del-Castillo (JM)

Department of Ophthalmology, Hospital Clinico de Madrid, Universidad Complutense, 28040 Madrid, Spain.

Stefano Barabino (S)

Centro Superficie Oculare e Occhio Secco, ASST Fatebenefratelli-Sacco, Ospedale L. Sacco, Università di Milano, 20157 Milan, Italy.

Rocio Herrero Vanrell (R)

Research Group (UCM 920415), Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal), Faculty of Pharmacy, Complutense University, 28040 Madrid, Spain.

Philippe Daull (P)

Ophthalmic Innovation Center, Santen SAS, 91058 Evry, France.

Jean-Sebastien Garrigue (JS)

Ophthalmic Innovation Center, Santen SAS, 91058 Evry, France.

Maurizio Rolando (M)

Ocular Surface Centre, ISPRE (Instituto di Medicina Oftalmica) Ophthalmic, 16129 Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH